Status:

RECRUITING

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Lead Sponsor:

Context Therapeutics Inc.

Conditions:

Platinum-resistant Ovarian Cancer

Testicular Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participant...

Detailed Description

The phase 1a Dose Escalation portion of the trial will enroll participants with PRROC, testicular, or endometrial cancer into one of approximately 9 dose escalation cohorts to assess safety, tolerabil...

Eligibility Criteria

Inclusion

  • Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.
  • Participants with measurable disease per RECIST 1.1.
  • ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.
  • Participants with adequate organ function.

Exclusion

  • Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.
  • Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.
  • Concurrent participation in another investigational clinical trial.

Key Trial Info

Start Date :

July 10 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2028

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT06515613

Start Date

July 10 2024

End Date

April 30 2028

Last Update

January 7 2026

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

University of Arkansas Winthrop P. Rockefeller Cancer Institute

Little Rock, Arkansas, United States, 72205

2

Precision NextGen Oncology & Research Center

Beverly Hills, California, United States, 90212

3

SCRI at Denver Health

Denver, Colorado, United States, 80218

4

John Theurer Cancer Center

Hackensack, New Jersey, United States, 07601